CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Sanofi-Aventis U.S. LLC v. Mylan Pharmaceuticals Inc.

1:17-cv-00024

Overview

Case Number 1:17-cv-00024
Filing Date 2017-01-10
Status Terminated
Termination Date 2018-01-02
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement

Parties

Defendant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Sanofi-Aventis U.S. LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6794410
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4β€²-trifluoromethylphenyl)-amide for treating multiple sclerosis
Filed: 2002-04-01
Issued: 2004-09-21
Expired (Term Ended) +1639d PTA
Expires: 2026-09-26
US9186346
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Filed: 2014-02-04
Issued: 2015-11-17
Active (7.2 yrs remaining)
Expires: 2034-02-04
US8802735
(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Filed: 2012-03-16
Issued: 2014-08-12
Active (5.3 yrs remaining)
Expires: 2032-03-16

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1639 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(2 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGEMENT filed against Mylan Inc., Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2062093.) - filed by Sanofi-Aventis U.S. LLC, Aventisub LLC, Sanofi, Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(nmg) (Entered: 01/10/2017)

Entry #1 • 2017-01-10
PACER Document

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 B2; US 8,802,735 B2. (nmg) (Entered: 01/10/2017)

Entry #4 • 2017-01-10
PACER Document

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc